Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo

Xin Shuai Wang, Li Zhang, Xiaocen Li, De Jiu Kong, Xiao Chen Hu, Xue Zhen DIng, Jun Qiang Yang, Meng Qi Zhao, Yixuan He, Kit Lam, She Gan Gao, Tzu-Yin Lin, Yuanpei Li

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer. Materials & methods: We prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity in vitro and in lung cancer-bearing mice. Results: Drug-loaded DCMs were relatively small in size, and possessed glutathione-responsive drug release. The combination of PTX-DCMs and AZD92921-DCMs exhibited strong synergistic effects in both cell line and in vivo without additional toxicity. Molecular studies demonstrated the synergistic modification in both IKB-α/NF-κB/Bcl-2 and EGFR/Akt pathways. Conclusion: The combination of DCM-loaded AZD9291 and PTX could potentially offer more effective and less toxicity treatment options for lung cancer patients.

Original languageEnglish (US)
Pages (from-to)1107-1120
Number of pages14
JournalNanomedicine
Volume13
Issue number10
DOIs
StatePublished - May 1 2018

Fingerprint

Micelles
Paclitaxel
Non-Small Cell Lung Carcinoma
Disulfides
cancer
Cells
toxicity
drug
Toxicity
Lung Neoplasms
Bearings (structural)
inhibitor
Pharmaceutical Preparations
Glutathione
AZD9291
Cell Line
Therapeutics

Keywords

  • AZD9291
  • EGFR inhibitor
  • NSCLC
  • paclitaxel

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)
  • Development

Cite this

Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo. / Wang, Xin Shuai; Zhang, Li; Li, Xiaocen; Kong, De Jiu; Hu, Xiao Chen; DIng, Xue Zhen; Yang, Jun Qiang; Zhao, Meng Qi; He, Yixuan; Lam, Kit; Gao, She Gan; Lin, Tzu-Yin; Li, Yuanpei.

In: Nanomedicine, Vol. 13, No. 10, 01.05.2018, p. 1107-1120.

Research output: Contribution to journalArticle

Wang, XS, Zhang, L, Li, X, Kong, DJ, Hu, XC, DIng, XZ, Yang, JQ, Zhao, MQ, He, Y, Lam, K, Gao, SG, Lin, T-Y & Li, Y 2018, 'Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo', Nanomedicine, vol. 13, no. 10, pp. 1107-1120. https://doi.org/10.2217/nnm-2017-0355
Wang, Xin Shuai ; Zhang, Li ; Li, Xiaocen ; Kong, De Jiu ; Hu, Xiao Chen ; DIng, Xue Zhen ; Yang, Jun Qiang ; Zhao, Meng Qi ; He, Yixuan ; Lam, Kit ; Gao, She Gan ; Lin, Tzu-Yin ; Li, Yuanpei. / Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo. In: Nanomedicine. 2018 ; Vol. 13, No. 10. pp. 1107-1120.
@article{eac1479a10c149ba997e6c80eb26f53b,
title = "Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo",
abstract = "Aim: This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer. Materials & methods: We prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity in vitro and in lung cancer-bearing mice. Results: Drug-loaded DCMs were relatively small in size, and possessed glutathione-responsive drug release. The combination of PTX-DCMs and AZD92921-DCMs exhibited strong synergistic effects in both cell line and in vivo without additional toxicity. Molecular studies demonstrated the synergistic modification in both IKB-α/NF-κB/Bcl-2 and EGFR/Akt pathways. Conclusion: The combination of DCM-loaded AZD9291 and PTX could potentially offer more effective and less toxicity treatment options for lung cancer patients.",
keywords = "AZD9291, EGFR inhibitor, NSCLC, paclitaxel",
author = "Wang, {Xin Shuai} and Li Zhang and Xiaocen Li and Kong, {De Jiu} and Hu, {Xiao Chen} and DIng, {Xue Zhen} and Yang, {Jun Qiang} and Zhao, {Meng Qi} and Yixuan He and Kit Lam and Gao, {She Gan} and Tzu-Yin Lin and Yuanpei Li",
year = "2018",
month = "5",
day = "1",
doi = "10.2217/nnm-2017-0355",
language = "English (US)",
volume = "13",
pages = "1107--1120",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "10",

}

TY - JOUR

T1 - Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo

AU - Wang, Xin Shuai

AU - Zhang, Li

AU - Li, Xiaocen

AU - Kong, De Jiu

AU - Hu, Xiao Chen

AU - DIng, Xue Zhen

AU - Yang, Jun Qiang

AU - Zhao, Meng Qi

AU - He, Yixuan

AU - Lam, Kit

AU - Gao, She Gan

AU - Lin, Tzu-Yin

AU - Li, Yuanpei

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Aim: This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer. Materials & methods: We prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity in vitro and in lung cancer-bearing mice. Results: Drug-loaded DCMs were relatively small in size, and possessed glutathione-responsive drug release. The combination of PTX-DCMs and AZD92921-DCMs exhibited strong synergistic effects in both cell line and in vivo without additional toxicity. Molecular studies demonstrated the synergistic modification in both IKB-α/NF-κB/Bcl-2 and EGFR/Akt pathways. Conclusion: The combination of DCM-loaded AZD9291 and PTX could potentially offer more effective and less toxicity treatment options for lung cancer patients.

AB - Aim: This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer. Materials & methods: We prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity in vitro and in lung cancer-bearing mice. Results: Drug-loaded DCMs were relatively small in size, and possessed glutathione-responsive drug release. The combination of PTX-DCMs and AZD92921-DCMs exhibited strong synergistic effects in both cell line and in vivo without additional toxicity. Molecular studies demonstrated the synergistic modification in both IKB-α/NF-κB/Bcl-2 and EGFR/Akt pathways. Conclusion: The combination of DCM-loaded AZD9291 and PTX could potentially offer more effective and less toxicity treatment options for lung cancer patients.

KW - AZD9291

KW - EGFR inhibitor

KW - NSCLC

KW - paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=85048688194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048688194&partnerID=8YFLogxK

U2 - 10.2217/nnm-2017-0355

DO - 10.2217/nnm-2017-0355

M3 - Article

C2 - 29874151

AN - SCOPUS:85048688194

VL - 13

SP - 1107

EP - 1120

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 10

ER -